LifeCycle Pharma Taps DeMartino to Lead Communications
Charting the future of public relations
Holmes Report
CEO

LifeCycle Pharma Taps DeMartino to Lead Communications

LifeCycle Pharma, an emerging specialty pharmaceutical company focused on developing and commercializing differentiated versions of existing drugs in therapeutic areas.

Paul Holmes

HORSHOLM, DENMARK—LifeCycle Pharma, an emerging specialty pharmaceutical company focused on developing and commercializing differentiated versions of existing drugs in therapeutic areas such as cardiovascular disease, organ transplantation and immunosuppression, has named Francesca DeMartino director of investor relations and corporate communications.

DeMartino will be based in the U.S. and will be responsible for developing, implementing and leading LCP´s investor relations and corporate communications strategic initiatives, including proactive communication with equity research analysts, shareholders, media, and other financial constituencies in order to raise the visibility of the Company among the investment community.

Prior to joining LCP, DeMartino was most recently director of investor relations at OMRIX Biopharmaceuticals. Earlier, she spent numerous years at leading investor relations and public relations agencies such as GCI Group and The Ruth Group.

View Style:

Load 3 More
comments powered by Disqus